Apolipoprotein B is associated with CT-angiographic progression beyond low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in patients with coronary artery disease.
Angiographic progression
Apolipoprotein B
Coronary artery disease
Lipoprotein cholesterol
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
09 Aug 2023
09 Aug 2023
Historique:
received:
26
03
2023
accepted:
07
07
2023
medline:
11
8
2023
pubmed:
10
8
2023
entrez:
9
8
2023
Statut:
epublish
Résumé
Accumulating evidence indicated that apolipoprotein B (apoB) was the principal lipid determinant of coronary artery disease (CAD). Nevertheless, the connection between apoB and angiographic progression of CAD remained undetermined. Five hundred and forty-four CAD patients with twice coronary computed tomography angiography experiences were enrolled. The Gensini scoring system was used to assess angiographic progression. Incident angiographic progression was defined as an annual change rate of the Gensini score of > 1 point. The predictive efficacy of baseline apoB levels for angiographic progression was assessed using a receiver operating characteristic (ROC) curve. For comparative purposes, patients were categorized into three groups according to their baseline apoB tertiles. Furthermore, discordance analyses defined by the median were performed to assess the superiority of apoB over lipoprotein cholesterol in predicting angiographic progression of CAD. Angiographic progression was observed in 184 patients (33.8%) during a follow-up period of 2.2-year. The area under the ROC curve was 0.565 (0.522-0.607, P = 0.013). The incidence of angiographic progression was elevated with increasing apoB tertile after adjusting for confounding factors [odds ratio (OR) for the medium apoB tertile: 1.92, 95% confidence interval (CI): 1.15-3.19, P = 0.012; OR for the high apoB tertile: 2.05, 95%CI:1.17-3.60, P = 0.013]. Additionally, discordance analyses showed that the higher apoB group had a significantly higher risk of CAD progression in the fully adjusted model (all P < 0.05). ApoB could be used as an accurate and comprehensive indicator of angiographic progression in patients with CAD.
Sections du résumé
BACKGROUND
BACKGROUND
Accumulating evidence indicated that apolipoprotein B (apoB) was the principal lipid determinant of coronary artery disease (CAD). Nevertheless, the connection between apoB and angiographic progression of CAD remained undetermined.
METHODS
METHODS
Five hundred and forty-four CAD patients with twice coronary computed tomography angiography experiences were enrolled. The Gensini scoring system was used to assess angiographic progression. Incident angiographic progression was defined as an annual change rate of the Gensini score of > 1 point. The predictive efficacy of baseline apoB levels for angiographic progression was assessed using a receiver operating characteristic (ROC) curve. For comparative purposes, patients were categorized into three groups according to their baseline apoB tertiles. Furthermore, discordance analyses defined by the median were performed to assess the superiority of apoB over lipoprotein cholesterol in predicting angiographic progression of CAD.
RESULTS
RESULTS
Angiographic progression was observed in 184 patients (33.8%) during a follow-up period of 2.2-year. The area under the ROC curve was 0.565 (0.522-0.607, P = 0.013). The incidence of angiographic progression was elevated with increasing apoB tertile after adjusting for confounding factors [odds ratio (OR) for the medium apoB tertile: 1.92, 95% confidence interval (CI): 1.15-3.19, P = 0.012; OR for the high apoB tertile: 2.05, 95%CI:1.17-3.60, P = 0.013]. Additionally, discordance analyses showed that the higher apoB group had a significantly higher risk of CAD progression in the fully adjusted model (all P < 0.05).
CONCLUSIONS
CONCLUSIONS
ApoB could be used as an accurate and comprehensive indicator of angiographic progression in patients with CAD.
Identifiants
pubmed: 37559117
doi: 10.1186/s12944-023-01872-6
pii: 10.1186/s12944-023-01872-6
pmc: PMC10410799
doi:
Substances chimiques
Apolipoproteins B
0
Cholesterol
97C5T2UQ7J
Cholesterol, LDL
0
lipoprotein cholesterol
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
125Subventions
Organisme : the Natural Science Foundation of Guangdong Province
ID : 2020A1515010362
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet. 2017;18(6):331–44.
doi: 10.1038/nrg.2016.160
pubmed: 28286336
pmcid: 5935119
Hoogeveen RC, Ballantyne CM. Residual Cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation. Clin Chem. 2021;67(1):143–53.
doi: 10.1093/clinchem/hvaa252
pubmed: 33257928
Jang AY, Lim S, Jo SH, Han SH, Koh KK. New Trends in Dyslipidemia Treatment. Circ J. 2021;85(6):759–68.
doi: 10.1253/circj.CJ-20-1037
pubmed: 33177309
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA et al. /ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e143.
Zeitouni M, Sabouret P, Kerneis M, Silvain J, Collet JP, Bruckert E, et al. 2019 ESC/EAS guidelines for management of dyslipidaemia: strengths and limitations. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):324–33.
doi: 10.1093/ehjcvp/pvaa077
pubmed: 32652000
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–504.
doi: 10.1056/NEJMoa040583
pubmed: 15007110
Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, et al. Apolipoprotein B particles and Cardiovascular Disease: a narrative review. JAMA Cardiol. 2019;4(12):1287–95.
doi: 10.1001/jamacardio.2019.3780
pubmed: 31642874
pmcid: 7369156
Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, et al. Association of triglyceride-lowering LPL variants and LDL-C-Lowering LDLR variants with risk of Coronary Heart Disease. JAMA. 2019;321(4):364–73.
doi: 10.1001/jama.2018.20045
pubmed: 30694319
pmcid: 6439767
Behbodikhah J, Ahmed S, Elyasi A, Kasselman LJ, De Leon J, Glass AD et al. Apolipoprotein B and Cardiovascular Disease: Biomarker and potential therapeutic target. Metabolites. 2021;11(10).
Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable mendelian randomisation analysis. PLoS Med. 2020;17(3):e1003062.
doi: 10.1371/journal.pmed.1003062
pubmed: 32203549
pmcid: 7089422
Su X, Cai X, Pan Y, Sun J, Jing J, Wang M, et al. Discordance of apolipoprotein B with low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol and coronary atherosclerosis. Eur J Prev Cardiol. 2022;29(18):2349–58.
doi: 10.1093/eurjpc/zwac223
pubmed: 36166398
van Rosendael AR, Bax AM, Smit JM, van den Hoogen IJ, Ma X, Al’Aref S, et al. Clinical risk factors and atherosclerotic plaque extent to define risk for major events in patients without obstructive coronary artery disease: the long-term coronary computed tomography angiography CONFIRM registry. Eur Heart J Cardiovasc Imaging. 2020;21(5):479–88.
doi: 10.1093/ehjci/jez322
pubmed: 32065624
pmcid: 7821703
Cuspidi C, Tadic M, Grassi G, Mancia G. Treatment of hypertension: the ESH/ESC guidelines recommendations. Pharmacol Res. 2018;128:315–21.
doi: 10.1016/j.phrs.2017.10.003
pubmed: 29080798
American Diabetes A. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):13–S28.
doi: 10.2337/dc19-S002
Abbara S, Blanke P, Maroules CD, Cheezum M, Choi AD, Han BK, et al. SCCT guidelines for the performance and acquisition of coronary computed tomographic angiography: a report of the society of Cardiovascular computed Tomography Guidelines Committee: endorsed by the North American Society for Cardiovascular Imaging (NASCI). J Cardiovasc Comput Tomogr. 2016;10(6):435–49.
doi: 10.1016/j.jcct.2016.10.002
pubmed: 27780758
Shui X, Chen Z, Wen Z, Tang L, Tang W, Liao Y, et al. Association of Atherogenic Index of plasma with angiographic progression in patients with suspected coronary artery disease. Angiology. 2022;73(10):927–35.
doi: 10.1177/00033197221080911
pubmed: 35229661
Xu L, Yan X, Tang Z, Feng B. Association between circulating oxidized OxLDL/LDL-C ratio and the severity of coronary atherosclerosis, along with other emerging biomarkers of cardiovascular disease in patients with type 2 diabetes. Diabetes Res Clin Pract. 2022;191:110040.
doi: 10.1016/j.diabres.2022.110040
pubmed: 35985428
Patel RS, Su S, Neeland IJ, Ahuja A, Veledar E, Zhao J, et al. The chromosome 9p21 risk locus is associated with angiographic severity and progression of coronary artery disease. Eur Heart J. 2010;31(24):3017–23.
doi: 10.1093/eurheartj/ehq272
pubmed: 20729229
pmcid: 3001587
Wilkins JT, Li RC, Sniderman A, Chan C, Lloyd-Jones DM. Discordance between apolipoprotein B and LDL-Cholesterol in young adults predicts coronary artery calcification: the CARDIA Study. J Am Coll Cardiol. 2016;67(2):193–201.
doi: 10.1016/j.jacc.2015.10.055
pubmed: 26791067
pmcid: 6613392
Shaya GE, Leucker TM, Jones SR, Martin SS, Toth PP. Coronary heart disease risk: low-density lipoprotein and beyond. Trends Cardiovasc Med. 2022;32(4):181–94.
doi: 10.1016/j.tcm.2021.04.002
pubmed: 33872757
Sandesara PB, Virani SS, Fazio S, Shapiro MD. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic Cardiovascular Disease Risk. Endocr Rev. 2019;40(2):537–57.
doi: 10.1210/er.2018-00184
pubmed: 30312399
Sinning D, Landmesser U. Is there a need to revise goals in the management of Dyslipidemias? Curr Cardiol Rep. 2019;21(6):51.
doi: 10.1007/s11886-019-1128-6
pubmed: 31041621
Stock J. Triglycerides and cardiovascular risk: apolipoprotein B holds the key. Atherosclerosis. 2019;284:221–2.
doi: 10.1016/j.atherosclerosis.2019.03.004
pubmed: 30914143
Glavinovic T, Sniderman AD. Apolipoprotein B: the Rosetta Stone of lipidology. Curr Opin Endocrinol Diabetes Obes. 2021;28(2):90–6.
doi: 10.1097/MED.0000000000000596
pubmed: 33229928
Gilliland TC, Liu Y, Mohebi R, Miksenas H, Haidermota S, Wong M, et al. Lipoprotein(a), oxidized phospholipids, and coronary artery Disease Severity and Outcomes. J Am Coll Cardiol. 2023;81(18):1780–92.
doi: 10.1016/j.jacc.2023.02.050
pubmed: 37137588
White-Al Habeeb NMA, Higgins V, Wolska A, Delaney SR, Remaley AT, Beriault DR. The Present and Future of lipid testing in Cardiovascular Risk Assessment. Clin Chem. 2023;69(5):456–69.
doi: 10.1093/clinchem/hvad012
pubmed: 37000150
Sniderman A, Langlois M, Cobbaert C. Update on apolipoprotein B. Curr Opin Lipidol. 2021;32(4):226–30.
doi: 10.1097/MOL.0000000000000754
pubmed: 33870931
Zuber V, Gill D, Ala-Korpela M, Langenberg C, Butterworth A, Bottolo L, et al. High-throughput multivariable mendelian randomization analysis prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease. Int J Epidemiol. 2021;50(3):893–901.
doi: 10.1093/ije/dyaa216
pubmed: 33130851
Ohwada T, Sakamoto T, Kanno Y, Yokokawa S, Amami K, Nakazato K, et al. Apolipoprotein B correlates with intra-plaque necrotic core volume in stable coronary artery disease. PLoS ONE. 2019;14(2):e0212539.
doi: 10.1371/journal.pone.0212539
pubmed: 30779793
pmcid: 6380558
Kim CW, Hong S, Chang Y, Lee JA, Shin H, Ryu S. Discordance between apolipoprotein B and low-density lipoprotein cholesterol and progression of coronary artery calcification in Middle Age. Circ J. 2021;85(6):900–7.
doi: 10.1253/circj.CJ-20-0692
pubmed: 33311006
Yao T, Lu W, Ke J, Zhang H, Zhao X, Song B, et al. Residual risk of coronary atherosclerotic heart disease and severity of coronary atherosclerosis assessed by ApoB and LDL-C in participants with statin treatment: a retrospective cohort study. Front Endocrinol (Lausanne). 2022;13:865863.
doi: 10.3389/fendo.2022.865863
pubmed: 35573992
Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and Cardiovascular Risk. JAMA. 2017;318(10):947–56.
doi: 10.1001/jama.2017.11467
pubmed: 28846118
pmcid: 5710502
Baik M, Nam HS, Heo JH, Lee HS, Kim YD. Differential association between apolipoprotein B and LDL cholesterol and cerebral atherosclerosis according to pre-stroke statin use. Atherosclerosis. 2023;371:14–20.
doi: 10.1016/j.atherosclerosis.2023.03.014
pubmed: 36966561
Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and Non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol. 2021;77(11):1439–50.
doi: 10.1016/j.jacc.2021.01.027
pubmed: 33736827
Lawler PR, Akinkuolie AO, Ridker PM, Sniderman AD, Buring JE, Glynn RJ, et al. Discordance between circulating atherogenic cholesterol Mass and Lipoprotein particle concentration in relation to future coronary events in women. Clin Chem. 2017;63(4):870–9.
doi: 10.1373/clinchem.2016.264515
pubmed: 28174174
pmcid: 5374022
Kostara CE, Papathanasiou A, Psychogios N, Cung MT, Elisaf MS, Goudevenos J, et al. NMR-based lipidomic analysis of blood lipoproteins differentiates the progression of coronary heart disease. J Proteome Res. 2014;13(5):2585–98.
doi: 10.1021/pr500061n
pubmed: 24689886
Sjogren P, Fredrikson GN, Samnegard A, Ericsson CG, Ohrvik J, Fisher RM, et al. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur Heart J. 2008;29(18):2218–26.
doi: 10.1093/eurheartj/ehn336
pubmed: 18664466
Khan SU, Khan MU, Valavoor S, Khan MS, Okunrintemi V, Mamas MA, et al. Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: systematic review and meta-analysis of trials. Eur J Prev Cardiol. 2020;27(12):1255–68.
doi: 10.1177/2047487319871733
pubmed: 31475865
Hagstrom E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, et al. Apolipoprotein B, residual Cardiovascular Risk after Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022;146(9):657–72.
doi: 10.1161/CIRCULATIONAHA.121.057807
pubmed: 35770629
pmcid: 9422774